Phase II trial to study anti-COVID-19 mAb CT-P59 completes enrolment
A trial of CT-P59, an anti-COVID-19 monoclonal antibody, has completed…
A trial of CT-P59, an anti-COVID-19 monoclonal antibody, has completed its enrolment and will study the treatment against standard-of-care.